As key members of the ubiquitin–proteasome system, DUBs play key roles in numerous cellular processes that are highly relevant to oncology, autoimmune disorders, and neurodegeneration.[61] The clinical development of DUB inhibitors is challenging, and most DUB inhibitors are in preclinical development.[61, 62, 63, 64] Two DUB small molecule inhibitors (VLX1570 and KSQ‐4279) have entered phase I clinical trials in malignant tumors (NCT02372240 and NCT05240898). This evidence concerns the gene ZUP1 and cancer.